Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease

Table 3

Meta-analysis.

Figures			Heterozygosity test
	Paricalcitol	Placebo	𝜒^2	𝑃	Pooled RR	95% CI	𝑍	𝑃
Figure 1	369	351	3.28	0.77	6.97	5.27–9.23	13.57	<0.00001
Figure 2	221	247	420.01	<0.00001	—	—	—	—
Figure 3	227	122	3.72	0.16	1.57	1.20–2.04	3.29	0.001
Figure 4	100	99	0.48	0.49	1.04	0.81–1.33	0.32	0.75
Figure 5	495	380	0.64	0.96	2.91	0.86–9.90	1.71	0.09
Figure 6	233	245	0.6	0.9	0.94	0.56–1.58	0.22	0.82
Figure 7	205	218	0.3	0.86	1.97	1.06–3.67	2.15	0.03